Concepedia

S. Hedgecock

SH

Statistics

Publications

4

Citations

2K

H-Index

4

Active since

2001

Affiliations

Novartis (United Kingdom)(Current)

Hôpital Antoine-Béclère

Hôpital Arnaud de Villeneuve

Johannes Gutenberg University Mainz

S. Hedgecock is an author at Novartis (United Kingdom) specializing in allergy, pharmacotherapy, and omalizumab therapy.

Publications per year

2001–2004

4

Publications

4

Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE

Marc Humbert, Richard Beasley, Jon G. Ayres et al. · Allergy · 2004 · 1.1K citations · Full text

, , +14

Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR

A M Vignola, Marc Humbert, Jean Bousquet et al. · Allergy · 2004 · 406 citations

, , +17

SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis

Thomas A. Luger, E.J.M. van Leent, Michael Graeber et al. · British Journal of Dermatology · 2001 · 244 citations · Full text

, , +13

Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis

Paul Chervinsky, Thomas B. Casale, Robert G. Townley et al. · Annals of Allergy Asthma & Immunology · 2003 · 213 citations

, , +14

1–4 of 4